<DOC>
	<DOCNO>NCT00005841</DOCNO>
	<brief_summary>RATIONALE : Vaccines make melanoma cell may make body build immune response kill tumor cell . Vaccine therapy plus filgrastim combine specific protein may effective treatment melanoma . PURPOSE : This phase I trial study side effect best dose vaccine therapy treat patient stage III stage IV melanoma completely remove surgery .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose filgrastim ( G-CSF ) -fetal liver tyrosine kinase-3 ( Flt3K ) fusion protein combine melanoma peptide vaccine comprise tyrosinase:368-376 peptide , gp100:209-217 antigen , MART-1:26-35 antigen emulsify Montanide ISA-51 patient completely resect stage III IV melanoma . II . Determine toxicity safety regimen patient . III . Determine immune response tyrosinase , MART-1 , gp100 antigen patient , , receive vaccination . OUTLINE : This dose escalation , multicenter study filgrastim ( G-CSF ) -fetal liver tyrosine kinase-3 ( Flt3K ) ( G-CSF-Flt3K ) fusion protein . Patients receive melanoma peptide vaccine comprise tyrosinase:368-376 peptide , gp100:209-217 antigen , MART-1:26-35 antigen emulsify Montanide ISA-51 subcutaneously ( SQ ) monthly 6 month , 9 12 month total 8 vaccination . Patients receive G-CSF-Flt3K fusion protein SQ daily 3 day , immediately , daily 6 day vaccination . Cohorts 6-10 patient receive escalate dos G-CSF-Flt3K fusion protein maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6-10 patient experience dose limit toxicity . Patients follow every 3 month year 2 resection , every 6 month 3 year , annually thereafter disease progression . PROJECTED ACCRUAL : A total 30-50 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove completely resect stage III IV cutaneous , mucosal , ocular melanoma Disease free , high risk relapse Must meet 1 follow criterion : Failed interferon alfa ( IFNA ) therapy Ineligible IFNA therapy Refused IFNA therapy HLAA2.1 positive Availability tumor tissue analysis gp100 antigen stain antibody HMB45 , expression tyrosinase MART1 antigens immunohistochemistry Tumor cell must positive least 1 antigen PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Hemoglobin least 9.0 g/dL Platelet count least 100,000/mm3 No coagulation bleed disorder Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 2.5 time upper limit normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No concurrent major medical illness cardiovascular system Pulmonary : No concurrent major medical illness respiratory system Immunologic : Hepatitis B surface antigen negative hepatitis C antibody negative HIV negative No history uveitis autoimmune inflammatory eye disease No active autoimmune disease No know allergic reaction Montanide ISA51 Other : No concurrent major systemic infection include pneumonia sepsis No concurrent major medical illness gastrointestinal system Not pregnant nursing Negative pregnancy test No malignancy within past 5 year except curatively treat squamous cell skin cancer carcinoma situ cervix allow 30 day treatment PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior tyrosinase:368376 peptide , gp100:209217 antigen , MART1:2635 antigen Chemotherapy : Not specify Endocrine therapy : No concurrent steroids Radiotherapy : At least 1 month since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 1 month since prior therapy , include adjuvant therapy , melanoma No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>